Angioedema

27 registered clinical trials studyying Angioedema — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients NCT07046806	Institute for Asthma and Allergy	Phase 1 / Phase 2
Recruiting	Lanadelumab in Long-term Prophylaxis of Acquired Angioedema NCT06818474	Bernstein Clinical Research Center	Phase 4
Unknown	Angioedema Biomarker Research Study NCT06210698	Foundation For Rare Disease Research	—
Completed	Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria NCT05936567	Incyte Corporation	Phase 2
Completed	A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With No NCT05578417	Takeda	—
Completed	Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency NCT06096077	Methodist Health System	—
Completed	A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic A NCT04444895	Shire	Phase 3
Terminated	Mepolizumab in Episodic Angioedema With Eosinophilia NCT04128371	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Unknown	Lanadelumab in Bradykinin Angioedema NCT04597944	University Hospital, Grenoble	—
Recruiting	Deployment o the Multidisciplinary Prospective Cohort Imminent NCT04334031	University Hospital, Lille	N/A
Completed	A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With N NCT04206605	Takeda	Phase 3
Recruiting	CLOUD-R HAE REGISTRY NCT03845946	University Hospital, Grenoble	—
Completed	Study of Clinical, Biological Characteristics and Quality of Life of Patients With Hereditary or Acquired Non NCT03240991	Centre Hospitalier Universitaire de Besancon	—
Completed	Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to NCT01723072	Novartis Pharmaceuticals	Phase 3
Completed	Determination of Specific Biomarkers of Angioneurotic Crisis NCT02833675	University Hospital, Grenoble	—
Completed	The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment NCT01371877	University of Nebraska	N/A
Unknown	Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedem NCT01036659	Bernstein, Jonathan A., M.D.	Phase 2
Completed	Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema NCT00876369	University of Nebraska	—
Completed	A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis NCT00890162	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema NCT00125541	Prothya Biosolutions	Phase 2 / Phase 3
Completed	C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema NCT00125151	Prothya Biosolutions	Phase 3
Unknown	The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema NCT00163839	Bayside Health	N/A
Completed	Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria NCT00385372	University Hospital Muenster	N/A
Completed	Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema NCT00097695	Shire	Phase 3
Completed	Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations NCT00004694	University of Iowa	N/A
Completed	AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study NCT01154361	Technical University of Munich	Phase 2
No Longer Available	Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-h NCT04583007	Shire	—